Odiparcil
- Generic Name
- Odiparcil
- Drug Type
- Small Molecule
- Chemical Formula
- C15H16O6S
- CAS Number
- 137215-12-4
- Unique Ingredient Identifier
- FIK1414ZI8
- Indication
Investigated for use/treatment in atrial fibrillation, cardiovascular disorders, thrombosis, and venous thromboembolism.
Inventiva Files 2024 Half-Year Report, Advancing Lanifibranor for MASH/NASH Treatment
• Inventiva has filed its Half-Year Report for the period ending June 30, 2024, with the French financial markets authority (AMF).
• The company's lead candidate, lanifibranor, is currently in a pivotal Phase III clinical trial (NATiV3) for treating MASH/NASH.
• Inventiva is reviewing options for odiparcil, a drug candidate for adult MPS VI patients, while focusing on lanifibranor development.
• Inventiva continues to explore opportunities to expand its pipeline, including selecting a candidate for its Hippo signaling pathway program.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath